Aurinia Pharmaceuticals
AUPH
11 hedge funds and large institutions have $19.3M invested in Aurinia Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
7.67% more ownership
Funds ownership: 0% → 7.67% (+7.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NEA Management Company
Timonium,
Maryland
|
+$9.05M |
| 2 |
Great Point Partners
Greenwich,
Connecticut
|
+$8.8M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$2.59M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$474K |
| 5 |
Cheyne Capital Management (UK)
London,
United Kingdom
|
+$380K |
Top Sellers
AUPH Hedge Fund Activity: Q3 2014 in Review
11 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2014, worth a combined $19.3M.
Buyers outnumbered sellers: 11 funds opened new AUPH positions and 0 closed out — a net gain of 11 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $9.05M.
- 11 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $19.3M of Aurinia Pharmaceuticals stock for Q3 2014.
- 11 funds opened new Aurinia Pharmaceuticals positions in Q3 2014 and 0 closed out, a net change of +11 holders.
- The largest Aurinia Pharmaceuticals buyer in Q3 2014 was NEA Management Company, an estimated $9.05M added.
Based on aggregated 13F filings for Q3 2014.